Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of NASH (2023)
5.2 Diagnostic and Biomarker Adoption Rates (2023)
5.3 Prescription Trends & Treatment Monitoring (2023), by Region
5.4 Healthcare Spending on NASH Diagnostics & Monitoring (2023)
5.5 Regulatory Landscape & Compliance (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Non-alcoholic Steatohepatitis Biomarkers Market Segmentation, By Type
7.1 Chapter Overview
7.2 Serum Biomarkers
7.2.1 Serum Biomarkers Market Trends Analysis (2020-2032)
7.2.2 Serum Biomarkers Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Oxidative Stress Biomarkers
7.3.1 Oxidative Stress Biomarkers Market Trends Analysis (2020-2032)
7.3.2 Oxidative Stress Biomarkers Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Hepatic Fibrosis Biomarkers
7.4.1 Hepatic Fibrosis Biomarkers Market Trends Analysis (2020-2032)
7.4.2 Hepatic Fibrosis Biomarkers Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Apoptosis Biomarkers
7.5.1 Apoptosis Biomarkers Market Trends Analysis (2020-2032)
7.5.2 Apoptosis Biomarkers Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.6.1 Others Market Trends Analysis (2020-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Non-alcoholic Steatohepatitis Biomarkers Market Segmentation, By End-use
8.1 Chapter Overview
8.2 Pharma & CRO Industry
8.2.1 Pharma & CRO Industry Market Trends Analysis (2020-2032)
8.2.2 Pharma & CRO Industry Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Diagnostic Labs
8.3.1 Diagnostic Labs Market Trends Analysis (2020-2032)
8.3.2 Diagnostic Labs Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Hospitals
8.4.1 Hospitals Market Trends Analysis (2020-2032)
8.4.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Academic Research Institutes
8.5.1 Academic Research Institutes Market Trends Analysis (2020-2032)
8.5.2 Academic Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.4 North America Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.5.2 USA Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.6.2 Canada Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.7.2 Mexico Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.5.2 Poland Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.6.2 Romania Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.4 Western Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.5.2 Germany Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.6.2 France Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.7.2 UK Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.8.2 Italy Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.9.2 Spain Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.12.2 Austria Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.4 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.5.2 China Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.5.2 India Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.5.2 Japan Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.6.2 South Korea Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.7.2 Vietnam Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.8.2 Singapore Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.9.2 Australia Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.4 Middle East Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.5.2 UAE Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.2.4 Africa Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.4 Latin America Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.5.2 Brazil Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.6.2 Argentina Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.7.2 Colombia Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Non-alcoholic Steatohepatitis Biomarkers Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10. Company Profiles
10.1 GENFIT
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Gilead Sciences
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 AstraZeneca
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 GE Healthcare
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Siemens Healthineers
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Bristol-Myers Squibb
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Pfizer Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Akero Therapeutics
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 89bio
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
